Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.
B-Cell Lymphoma|B-Cell Leukemia
DRUG: PCI-32765
Dose limiting toxicity assessment for each patient., At the end of the first 35 day cycle|Adverse events, 30 days after last dose of study drug|Pharmacokinetic/ Pharmacodynamic assessments, during Cycle 1
Tumor response, at the end of Cycles 2, 4, and 6 unitl progression
The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.